Healthy Returns: The launch of breakthrough Alzheimer's drug Leqembi is off to a slow start
==========

The launch of the Alzheimer's drug Leqembi is off to a slow start, with only about 2,000 patients currently on the drug, seven months after FDA approval. Biogen had set a target of treating 10,000 patients by the end of March. The complex process for patients to receive Leqembi, including securing an appointment with a neurologist and undergoing special tests, is a hurdle. Biogen estimates that 3,800 patients have signed up on registries to receive the drug. The company is also working on an injectable version of Leqembi. Leqembi brought in $7 million in fourth-quarter revenue and $10 million in full-year sales. Biogen is pinning its hopes on Leqembi to drive growth as it faces generic competition for its multiple sclerosis therapies.

#Alzheimer's #Leqembi #DrugLaunch #Biogen #FdaApproval

https://www.cnbc.com/2024/02/20/healthy-returns-alzheimers-drug-leqembi-launch-apple-vision-pro-nausea.html